American Brivision (Holding) (OTCMKTS:ABVC) Rating Increased to Buy at ValuEngine

ValuEngine upgraded shares of American Brivision (Holding) (OTCMKTS:ABVC) from a hold rating to a buy rating in a report published on Thursday morning, ValuEngine reports.

Shares of American Brivision (Holding) stock traded down $0.50 during trading on Thursday, reaching $11.00. The company’s stock had a trading volume of 450 shares, compared to its average volume of 149. American Brivision has a 12-month low of $5.50 and a 12-month high of $37.80. The business’s 50 day simple moving average is $11.94.

American Brivision (Holding) (OTCMKTS:ABVC) last posted its quarterly earnings results on Tuesday, May 28th. The company reported ($0.05) earnings per share for the quarter. The company had revenue of $0.21 million during the quarter.

American Brivision (Holding) Company Profile

American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company's licensed products include ABV-1501, a combination therapy for triple negative breast cancer; ABV-1502, a combination therapy for solid tumors with Anti-PD1; ABV-1503, a combination therapy for chronic lymphocytic leukemia; ABV-1504 for depressive disorders; ABV-1505, a combination therapy for attention deficit hyperactivity disorder; BFC-1401, a vitreous substitute for vitrectomy; and Maitake combination therapy.

See Also: Dividend Yield

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for American Brivision (Holding) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Brivision (Holding) and related companies with MarketBeat.com's FREE daily email newsletter.